Recommendation to update the British Society for Cutaneous Allergy corticosteroid series
Clinical and Experimental Dermatology · 2023
DOI: 10.1093/ced/llac115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Sarah E Morrow und 19 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology Oxford University Hospitals NHS Trust, Oxford, UK. Hauptthemen laut MEDLINE: Dermatitis, Allergic Contact, Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Patch testing is an important investigation when dermatitis is unresponsive to, or worsened by, topical corticosteroid treatment. There is a balance to be struck between testing too many allergens, which is expensive, time consuming and risks causing sensitization, and testing too few, which risks missing the diagnosis. The current British Society for Cutaneous Allergy (BSCA) corticosteroid series comprises eight allergens and was last updated in February 2007.
Aim
To review and update the BSCA corticosteroid series.
Methods
We retrospectively analysed data from 16 patch test centres in the UK and Ireland for all patients who were patch tested to a corticosteroid series between August 2017 and July 2019. We recorded the allergens tested, the number and percentage tested to a corticosteroid series and the number of positive results for each allergen. We identified the allergens that test positive in ≥ 0.1% of selectively tested patients.
Results
Overall, 3531 patients were tested to a corticosteroid series in the 16 centres. The number of allergens tested ranged from 7 to 18 (mean 10). The proportion of patch test patients who were tested to a corticosteroid series ranged from 1% to 99%. Six allergens in the 2017 BSCA series tested positive in ≥ 0.1% of patients. Nine allergens not in the BSCA corticosteroid series tested positive in ≥ 0.1% of patients.
Conclusion
This audit demonstrates the importance of regular review of recommended series and the significant variations in practice. The new BSCA corticosteroid series that we recommend contains 13 haptens, with the addition of the patient’s own steroid creams as appropriate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Dermatology Oxford University Hospitals NHS Trust, Oxford, UK.
- Leeds Teaching Hospitals NHS Trust, Leeds, UK.
- South Infirmary Victoria University Hospital, Cork, Ireland.
- NHS Lothian, Edinburgh, UK.
- Sulis Hospital, Bath, UK.
- University Hospital of Wales, Cardiff, UK.
Zitieren
APA
Morrow, S. E., Arianayagam, S., Wilkinson, M., Bourke, J., Bertram, C. G., Buckley, D. A., Chowdhury, M. M. U., Divekar, P., Ghaffar, S. A., Green, C., Holden, C., Johnston, G. A., Mughal, A., Dhonncha, E. N., Reckling, C., Scharrer, K., Stone, N., Thompson, D., Wakelin, S., & Cooper, S. (2023). Recommendation to update the British Society for Cutaneous Allergy corticosteroid series. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llac115
Vancouver
Morrow SE, Arianayagam S, Wilkinson M, Bourke J, Bertram CG, Buckley DA, et al. Recommendation to update the British Society for Cutaneous Allergy corticosteroid series. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llac115
BibTeX
@article{Morrow2023,
author = {Morrow, Sarah E and Arianayagam, Sanju and Wilkinson, Mark and Bourke, John and Bertram, Chandra Gooptu and Buckley, Deirdre A and Chowdhury, Mahbub M U and Divekar, Preshita and Ghaffar, Sharizan Abdul and Green, Cathy and Holden, Catherine and Johnston, Graham A and Mughal, Avad and Dhonncha, Eilis Nic and Reckling, Christine and Scharrer, Krisztina and Stone, Natalie and Thompson, Donna and Wakelin, Sarah and Cooper, Susan},
title = {Recommendation to update the British Society for Cutaneous Allergy corticosteroid series},
journal = {Clinical and Experimental Dermatology},
year = {2023},
doi = {10.1093/ced/llac115}
}
EUVIMED